Last reviewed · How we verify
Expanded antimicrobial therapy — Competitive Intelligence Brief
phase 3
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Expanded antimicrobial therapy (Expanded antimicrobial therapy) — University of Virginia. Expanded antimicrobial therapy uses a broadened spectrum of antimicrobial agents to treat infections caused by multiple pathogenic organisms simultaneously.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Expanded antimicrobial therapy TARGET | Expanded antimicrobial therapy | University of Virginia | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Expanded antimicrobial therapy CI watch — RSS
- Expanded antimicrobial therapy CI watch — Atom
- Expanded antimicrobial therapy CI watch — JSON
- Expanded antimicrobial therapy alone — RSS
Cite this brief
Drug Landscape (2026). Expanded antimicrobial therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/expanded-antimicrobial-therapy. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab